Evidence map›Paper›PMID 26121196›Full record

ReviewNature medicine2015

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Michele W L Teng, Edward P Bowman, Joshua J McElwee, Mark J Smyth, Jean-Laurent Casanova, Andrea M Cooper, Daniel J Cua

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 459 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
459citing papers in PubMed, 5 pooled it
33.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

459 citing papers in PubMed, 5 syntheses or guidelines pooled it, 843 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

399 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Michele W L Teng1] Cancer Immunoregulation and Immunotherapy and Immunology in Cancer and Infection Laboratories, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. [2] School of Medicine, University of Queensland, Herston, Queensland, Australia.ORCID 0000000318869145
Edward P BowmanMerck Research Laboratories, Palo Alto, California, USA.
Joshua J McElweeMerck Research Laboratories, Boston, Massachusetts, USA.
Mark J Smyth1] Cancer Immunoregulation and Immunotherapy and Immunology in Cancer and Infection Laboratories, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. [2] School of Medicine, University of Queensland, Herston, Queensland, Australia.
Jean-Laurent Casanova1] St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, New York, USA. [2] Howard Hughes Medical Institute, New York, New York, USA. [3] Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Paris, France. [4] Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, Paris, France. [5] Paris Descartes University, Imagine Institute, Paris, France.
Andrea M CooperTrudeau Institute, Inc., Saranac Lake, New York, USA.
Daniel J CuaMerck Research Laboratories, Palo Alto, California, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USThe University of Queensland · AUHoward Hughes Medical Institute · USTrudeau Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cytokine interleukin-12 (IL-12) was thought to have a central role in T cell-mediated responses in inflammation for more than a decade after it was first identified. Discovery of the cytokine IL-23, which shares a common p40 subunit with IL-12, prompted efforts to clarify the relative contribution of these two cytokines in immune regulation. Ustekinumab, a therapeutic agent targeting both cytokines, was recently approved to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders. Here we discuss the therapeutic rationale for targeting these cytokines, the unintended consequences for host defense and tumor surveillance and potential ways in which these therapies can be applied to treat additional immune disorders.

Indexed as

ImmunityMolecular Targeted TherapyAnimalsHumansImmunologic SurveillanceInflammationInterleukin-12Interleukin-23Interleukin-12Interleukin-23

Identifiers

PMID26121196
OpenAlexW1488772574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.